79 related articles for article (PubMed ID: 21431842)
1. Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers.
Hasegawa K; Torii Y; Ishii R; Oe S; Kato R; Udagawa Y
Arch Gynecol Obstet; 2011 Dec; 284(6):1515-21. PubMed ID: 21431842
[TBL] [Abstract][Full Text] [Related]
2. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
Hasegawa K; Ohashi Y; Ishikawa K; Yasue A; Kato R; Achiwa Y; Nishio E; Udagawa Y
Int J Oncol; 2005 May; 26(5):1419-28. PubMed ID: 15809736
[TBL] [Abstract][Full Text] [Related]
3. The effects of the selective cyclooxygenase-2 inhibitor on endometrial cytological findings in uterine endometrial cancer patients.
Hasegawa K; Kawamura K; Kato R; Komiyama S; Kaneko C; Udagawa Y
Acta Cytol; 2012; 56(4):394-400. PubMed ID: 22846758
[TBL] [Abstract][Full Text] [Related]
4. Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.
Hasegawa K; Ishikawa K; Kawai S; Torii Y; Kawamura K; Kato R; Tsukada K; Udagawa Y
Oncol Rep; 2013 Dec; 30(6):2937-44. PubMed ID: 24100466
[TBL] [Abstract][Full Text] [Related]
5. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M
Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386
[TBL] [Abstract][Full Text] [Related]
6. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T
Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837
[TBL] [Abstract][Full Text] [Related]
7. A window-of-opportunity biomarker study of etodolac in resectable breast cancer.
Schwab RB; Kato S; Crain B; Pu M; Messer K; Weidner N; Blair SL; Wallace AM; Carson DA; Parker BA
Cancer Med; 2015 Oct; 4(10):1583-8. PubMed ID: 26275572
[TBL] [Abstract][Full Text] [Related]
8. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas.
Masciullo V; Susini T; Zamparelli A; Bovicelli A; Minimo C; Massi D; Taddei G; Maggiano N; De Iaco P; Ceccaroni M; Bovicelli L; Amunni G; Mancuso S; Scambia G; Giordano A
Clin Cancer Res; 2003 Nov; 9(14):5332-8. PubMed ID: 14614018
[TBL] [Abstract][Full Text] [Related]
9. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Matsunaga N; Yamada N; Ohira M; Tachimori A; Nishiguchi Y; Nishino H; Seki S; Hirakawa K
Oncol Rep; 2004 Jan; 11(1):167-71. PubMed ID: 14654921
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Nasir A; Boulware D; Kaiser HE; Lancaster JM; Coppola D; Smith PV; Hakam A; Siegel SE; Bodey B
In Vivo; 2007; 21(1):35-43. PubMed ID: 17354612
[TBL] [Abstract][Full Text] [Related]
15. Expression of mTOR protein and its clinical significance in endometrial cancer.
No JH; Jeon YT; Park IA; Kang D; Kim JW; Park NH; Kang SB; Song YS
Med Sci Monit; 2009 Oct; 15(10):BR301-305. PubMed ID: 19789507
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle regulators and apoptosis-associated proteins in relation to proliferative activity and degree of apoptosis in HNPCC versus sporadic endometrial carcinoma.
Rijcken F; van der Zee A; van der Sluis T; Boersma-van Ek W; Kleibeuker J; Hollema H
Histopathology; 2006 Feb; 48(3):275-85. PubMed ID: 16430474
[TBL] [Abstract][Full Text] [Related]
17. Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines.
Noda M; Tatsumi Y; Tomizawa M; Takama T; Mitsufuji S; Sugihara H; Kashima K; Hattori T
J Gastroenterol; 2002; 37(11):896-904. PubMed ID: 12483244
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Fakhry H; Miyamoto T; Kashima H; Suzuki A; Ke H; Konishi I; Shiozawa T
Hum Pathol; 2010 Jun; 41(6):848-58. PubMed ID: 20178884
[TBL] [Abstract][Full Text] [Related]
19. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
20. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
